The Role of Fine-Scale Habitat Associations in Structuring Spider Assemblages: Determinants of Spatial Patterns in Community Composition

Elucidating the ecological determinants of community structure and how they vary spatially has a long history in ecology, but there still is no consensus on the mechanisms behind diversity patterns. The primary objective of this dissertation was to focus on spider assemblages to investigate how the fine-scale habitat associations of organisms may drive their community composition at larger scales. Research was conducted in the Bear River Mountains, Utah, in an attempt to elucidate the potential role of species-microhabitat associations in driving three well-known patterns of community composition that have typically been investigated at broad scales: 1) elevation gradients of species diversity, 2) the response of species assemblages to neighboring habitat structure and 3) community composition at the edges of habitat patches. Slope aspect was a significant predictor of spider density and species richness when communities were compared at the same elevation, suggesting that fine-scale topographic variables may play an important role in shaping elevational patterns of species composition. Cursorial spider composition was strongly linked to site temperature only, whereas differences across web spider assemblages significantly increased with dissimilarities in woody plant cover and temperature. The study on the effects of neighboring habitat structure revealed markedly reduced cursorial spider densities in shrubs without surrounding structure, and more cursorial species in control shrubs, whereas web spiders lacked any significant response to treatments. These contrasting responses indicate that data should be collected at larger spatial extents for mobile species, and that mobility may mediate the outcome of surrounding habitat modifications on the local composition of communities. In the last study, I focused on communities in which the edge-dwelling spiders Theridion and Dictyna strongly differed in terms of concealment and substrate generalization and found that microhabitat choice may affect the sensitivity of species to habitat geometry, a characteristic associated with habitat fragmentation. This work suggests that a better understanding of the links between the biological traits of species and their fine-scale environmental requirements may help uncover the mechanisms behind spatial patterns of community composition at larger scales

Ubiquitous LEA29Y Expression Blocks T Cell Co-Stimulation but Permits Sexual Reproduction in Genetically Modified Pigs

We have successfully established and characterized a genetically modified pig line with ubiquitous expression of LEA29Y, a human CTLA4-Ig derivate. LEA29Y binds human B7.1/CD80 and B7.2/CD86 with high affinity and is thus a potent inhibitor of T cell co-stimulation via this pathway. We have characterized the expression pattern and the biological function of the transgene as well as its impact on the porcine immune system and have evaluated the potential of these transgenic pigs to propagate via assisted breeding methods. The analysis of LEA29Y expression in serum and multiple organs of CAG-LEA transgenic pigs revealed that these animals produce a biologically active transgenic product at a considerable level. They present with an immune system affected by transgene expression, but can be maintained until sexual maturity and propagated by assisted reproduction techniques. Based on previous experience with pancreatic islets expressing LEA29Y, tissues from CAG-LEA29Y transgenic pigs should be protected against rejection by human T cells. Furthermore, their immune-compromised phenotype makes CAG-LEA29Y transgenic pigs an interesting large animal model for testing human cell therapies and will provide an important tool for further clarifying the LEA29Y mode of action

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Patch Shape Alters Spider Community Structure: Links Between Microhabitat Choice and Sensitivity to Increased Edge Habitat

Increased edge effects in fragmented habitats can affect the abundance of edge-dwelling organisms, but these impacts may depend on the biological attributes of species. Microhabitat choice, a species characteristic that reflects combinations of biological traits, may affect the ability of peripheral species to take advantage of increased edge habitat in the presence of edge effects. In this field study, we built artificial shrub modules designed to encourage web spiders to build webs on the periphery. While modules were identical in volume, they differed in shape (cubic and elongated), so that elongated modules had more edge habitat and were subject to enhanced edge effects. Given that the tangle-web spiders Theridion and Dictyna built webs on module edges and strongly differed in terms of concealment and substrate generalization, two habitat characteristics associated with lower vulnerability to habitat modification, we tested the hypothesis that Theridion, which built webs in more concealed locations and on a greater diversity of substrate configurations in the modules compared to Dictyna, would take better advantage of increased edge habitat. As predicted, Theridion was significantly more abundant on elongated modules whereas the abundance of Dictyna did not respond to shape, even though the change in module shape entailed a similar increase in favored substrate for both spider groups. Our results suggest that the microhabitat associations of organisms may be linked to their propensity to be sensitive to edges, and that a better understanding of these links can improve our ability to predict the effects of habitat modification on biodiversity

The host becomes dinner: possible use of Cyclosa as a nuptial gift by Argyrodes in a colonial web

Volume: 38Start Page: 132End Page: 13

Increased transplant arteriosclerosis in the absence of CCR7 is associated with reduced expression of Foxp3.

BACKGROUND: The chemokine receptor CCR7 plays a pivotal role in the homing of naïve T cells and regulatory T cells to secondary lymphoid organs and the migration of dendritic cells into afferent lymphatic vessels. Antigen presentation, T cell recruitment, and expansion of regulatory cells are crucial events in establishing and controlling chronic allograft dysfunction. In this study, we report an important role for chemokine receptor CCR7 in the development of transplant arteriosclerosis. METHODS: Fully major histocompatibility complex-mismatched CBA (H2) donor aortas were transplanted into BALB/c-CCR7 (H2), BALB/c-CCR7 (H2), or BALB/c-CCR7 (H2) recipients. Grafts were analyzed by histology, morphometry, and immunofluorescence on day 30 after transplantation. Intragraft cytokine mRNA production was analyzed by realtime polymerase chain reaction on day 14 after transplantation. RESULTS: After implanting fully major histocompatibility complex-mismatched donor aortas into CCR7-deficient recipients, transplant arteriosclerosis was significantly elevated. CD4 depletion resulted in a reduction of intima proliferation in CCR7 recipients whereas CD8 depletion had no effect. Analysis of aortic grafts from CCR7 recipients revealed high numbers of infiltrating CD4, F4/80, and CD205 cells. Furthermore, intragraft cytokine production showed higher levels of interleukin-4, interleukin-12, and eotaxin mRNA expression, whereas significantly lower Foxp3 mRNA expression was observed in CCR7 recipients. CONCLUSION: These data suggest that although alloantigen presentation in secondary lymphoid organs is hampered in CCR7-deficient recipients, this process may take place within the allograft itself, leading to increased formation of transplant arteriosclerosis. The decrease in Foxp3 expression despite increased in CD4 T cell infiltration indicates a reduction in T regulatory cells possibly influencing the intensity of the graft rejection